1174713-22-4

Basic information

• Product Name: C₂₉H₃₁N₂O⁽¹⁺⁾*Cl^(1-)
• CAS NO: 1174713-22-4
• Molecular Weight: 459.031
• Mol File: 1174713-22-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: C₂₉H₃₁N₂O⁽¹⁺⁾*Cl^(1-)(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₉H₃₁N₂O⁽¹⁺⁾*Cl^(1-)(1174713-22-4)
• EPA Substance Registry System: C₂₉H₃₁N₂O⁽¹⁺⁾*Cl^(1-)(1174713-22-4)

Safety Data

• Hazardous Substances Data: 1174713-22-4(Hazardous Substances Data)

Upstream product

• 1023903-94-7 3,6-di(piperidin-1-yl)-9H-xanthen-9-one 
• 100-58-3 phenylmagnesium bromide 

Relevant articles and documents

ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER

The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R1 represents aryl, Het1 or C1-6 alkyl, which latter group is optionally substituted by aryl or Het2; R2a and R2b together form C3.8n-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C1-4 alkyl, C(O)OH and C(O)O-C1-4, alkyl.and which alkylene group is optionally interrupted by X1; R3a and R3b together form C3-6 /7-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C1-4 alkyl, C(O)OH and C(O)O-C1-4 alkyl, and which alkylene group is optionally interrupted by X2; X1 and X2 independently represent O, S, or NR4; R4 represents, independently at each occurrence, H, C(O)OR5, C(0)R6a, C(O)N(R6b)R6c or C1-6, alkyl, which latter group is optionally substituted by one or more substituents selected from halo, aryl and Het3 or is substituted by a single C(0)0R1a group; R4a represents H or C1-4 alkyl; R5 represents aryl, Het4 or C1-6 alkyl optionally substituted by one or more substituents selected from halo, aryl and Het5; R5e to R6d independently represent H or R5; each aryl independently represents a C6-10 carbocyclic aromatic group, which group may comprise either one or two rings and may be substituted by one or more substituents selected from halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR7, phenyl, naphthyl and Het6) and OR8; R7 and R8 independently represent H, C1-4 alkyl (optionally substituted by one or more halo groups or by a single phenyl or C(O)OR8a substituent), Het7, phenyl or naphthyl; R8a represents H or C1-4 alkyl; Het1 to Het7 independently represent 5- to 10-membered aromatic, fully saturated or partially unsaturated heterocyclic groups containing one or.more heteroatoms selected from oxygen, nitrogen and/or sulfur, which heterocyclic groups may comprise one or two rings and may be substituted by one or more substituents selected from Halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR9 and phenyl) and OR10; R9 and R10 independently represent H, C1-4 alkyl or phenyl; unless otherwise specified, alkyl groups are optionally substituted by one or more halo atoms; and A' represents a pharmaceutically acceptable anion. Also disclosed are methods for making and using ' compounds as well as pharmaceutical compositions.